Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Vericel Corp Ord is a biotechnology business based in the US. Vericel Corp Ord shares (VCEL) are listed on the NASDAQ and all prices are listed in US Dollars. Vericel Corp Ord employs 281 staff and has a trailing 12-month revenue of around $159.3 million.
Finder Award
SoFi Invest
Robinhood
tastyworks
| Latest market close | $28.53 |
|---|---|
| 52-week range | $17.30 - $43.97 |
| 50-day moving average | $24.42 |
| 200-day moving average | $26.65 |
| Wall St. target price | $35.50 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.24 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $28.53 from 2023-01-27
| 1 week (2023-01-24) | -0.42% |
|---|---|
| 1 month (2022-12-30) | 8.31% |
| 3 months (2022-10-31) | 6.14% |
| 6 months (2022-07-29) | -12.32% |
| 1 year (2022-01-28) | -14.27% |
|---|---|
| 2 years (2021-01-29) | -30.87% |
| 3 years (2020-01-31) | 73.96% |
| 5 years (2018-01-30) | 288.16% |
| Revenue TTM | $159.3 million |
|---|---|
| Gross profit TTM | $106 million |
| Return on assets TTM | -5.03% |
| Return on equity TTM | -10.82% |
| Profit margin | -11.36% |
| Book value | $3.77 |
| Market capitalisation | $1.3 billion |
TTM: trailing 12 months
We're not expecting Vericel Corp Ord to pay a dividend over the next 12 months.
Vericel Corp Ord's shares were split on a 1:20 basis on 15 October 2013. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Vericel Corp Ord shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Vericel Corp Ord shares which in turn could have impacted Vericel Corp Ord's share price.
Over the last 12 months, Vericel Corp Ord's shares have ranged in value from as little as $17.3 up to $43.97. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vericel Corp Ord's is 1.751. This would suggest that Vericel Corp Ord's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. .
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.